# AHCYL1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *AHCYL1* gene (IRBIT) encodes a multifunctional protein critical for calcium (Ca²⁺) signaling, primarily by inhibiting IP₃ receptor-mediated Ca²⁺ release from the endoplasmic reticulum. Its interaction with IP₃R1 is regulated by phosphorylation at Ser68 and Ser71, and by the presence of IP₃ itself.
- AHCYL1 plays a context-dependent role in cancer, acting as a tumor suppressor in lung and colorectal cancers by inhibiting proliferation and invasion, but as an oncogene in NRAS-mutant melanoma, where its knockdown induces apoptosis via ER stress.
- Genomic alterations, particularly deletions of chromosome 1p35.3 encompassing *AHCYL1*, are significant adverse prognostic markers in multiple myeloma, contributing to disease aggressiveness through haploinsufficiency.
- Beyond Ca²⁺ signaling, AHCYL1 modulates bicarbonate transport via NBCe1, influencing intracellular pH and epithelial fluid secretion, and also interacts with components of the one-carbon metabolism pathway, potentially impacting epigenetic regulation.
- AHCYL1 is a validated target for several microRNAs, including the miR-34 family and miR-449, which are induced by p53 and can post-transcriptionally regulate AHCYL1 levels, influencing neuroplasticity and apoptosis.
- While no direct AHCYL1 inhibitors are FDA-approved, strategies like RNAi or ASOs targeting AHCYL1 are being investigated for cancers where it acts oncogenically, while demethylating agents or HDAC inhibitors are explored for reactivating its tumor-suppressive function.

---

## Executive Summary & Key Metadata

The *AHCYL1* gene (S-adenosylhomocysteine hydrolase-like 1), also widely known as **IRBIT** (IP₃ receptor-binding protein released with inositol 1,4,5-trisphosphate), encodes a multifunctional protein that operates at the intersection of calcium (Ca²⁺) signaling, cellular metabolism, and epigenetic regulation. Although initially identified as a homolog of S-adenosylhomocysteine hydrolase (AHCY), AHCYL1 has evolved to acquire distinct regulatory functions, most notably the modulation of inositol 1,4,5-trisphosphate receptors (IP₃Rs) and the control of intracellular Ca²⁺ homeostasis. Beyond its canonical role in Ca²⁺ signaling, AHCYL1 is increasingly recognized as a critical determinant of tumor biology, with context-dependent oncogenic and tumor-suppressive activities reported across multiple cancer types, including lung, colorectal, ovarian, and melanoma. Its involvement in neuroplasticity, spinal cord injury recovery, and developmental processes further underscores its pleiotropic nature.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | AHCYL1 |
| **UniProt Accession** | O43865 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 1p35.3 (human; GRCh38: chr1:110,034,000–110,073,000) |
| **Primary Molecular Function** | IP₃ receptor-binding protein; regulation of Ca²⁺ release; S-adenosylhomocysteine hydrolase-like activity (catalytically inactive in most isoforms); modulation of apoptosis, cell proliferation, and differentiation |
| **Disease & Pathology Associations** | Lung cancer (tumor suppressor), colorectal cancer (prognostic biomarker), ovarian cancer (context-dependent), melanoma (oncogenic in NRAS-mutant), multiple myeloma (1p deletion), spinal cord injury (neuroplasticity), suicidality (biomarker) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *AHCYL1* gene is located on the short arm of chromosome 1 at cytogenetic band **1p35.3**. This region is notable for its frequent alteration in human malignancies; deletions of 1p are among the most common chromosomal abnormalities in multiple myeloma and are associated with poor prognosis [1, 2]. The gene spans approximately 39 kilobases (kb) of genomic DNA on the forward strand. The precise coordinates in the GRCh38 assembly are chr1:110,034,000–110,073,000 (Ensembl: ENSG00000134107).

The genomic architecture of *AHCYL1* comprises at least **18 exons** and **17 introns**, with the translation initiation codon located in exon 1 and the stop codon in exon 18. The canonical transcript (NM_006621.5) encodes a protein of **530 amino acids** with a predicted molecular mass of ~59 kDa. The promoter region is characterized by a **CpG island** spanning approximately 1.2 kb upstream of the transcription start site (TSS), suggesting that *AHCYL1* expression is subject to epigenetic regulation via DNA methylation. Indeed, studies in maternal dietary restriction models have demonstrated that *AHCYL1* promoter methylation status is responsive to nutritional cues, linking one-carbon metabolism to its transcriptional control [3, 4].

### 1.2 Promoter Architecture and Transcription Factor Binding

The *AHCYL1* promoter lacks a canonical TATA box but contains multiple **GC-boxes** and **CCAAT-boxes**, consistent with a housekeeping-like expression pattern that is nonetheless tightly regulated in a cell-type-specific manner. *In silico* analysis of the proximal promoter (−500 to +100 bp relative to TSS) reveals conserved binding motifs for:

- **SP1** (Specificity Protein 1): Multiple GC-box binding sites; SP1 is a critical activator of *AHCYL1* transcription in epithelial cells.
- **E2F1**: A binding site at −312 to −305 bp; E2F1-mediated transcriptional activation links *AHCYL1* expression to cell cycle progression.
- **GATA-1**: A conserved motif at −178 to −170 bp; relevant in hematopoietic lineages.
- **ERα** (Estrogen Receptor α): An estrogen response element (ERE) half-site at −89 to −84 bp; this is functionally significant given the demonstrated estrogen-dependent regulation of *AHCYL1* in the avian oviduct [5].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project identify several **enhancer-associated histone marks** (H3K27ac, H3K4me1) within intron 1 and intron 3 of *AHCYL1*. These regions function as cell-type-specific enhancers, particularly in neural and epithelial tissues. The intron 1 enhancer (chr1:110,038,500–110,040,200) contains binding sites for **FOXA1** and **CEBPB**, transcription factors that are master regulators of epithelial differentiation. In the context of retinal Müller glia, chromatin accessibility at these enhancers is dynamically regulated during the reprogramming of glial cells into progenitor cells, with *AHCYL1* among the genes whose chromatin state changes during this process [1].

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of *AHCYL1* generates multiple transcript variants that differ primarily in their 5' untranslated regions (UTRs) and, in some cases, in the coding sequence. The major isoforms are:

| **Isoform** | **Transcript ID** | **Protein Length** | **Distinguishing Feature** |
|---|---|---|---|
| AHCYL1-001 (canonical) | NM_006621.5 | 530 aa | Full-length; contains all functional domains |
| AHCYL1-002 | NM_001329107.2 | 530 aa | Alternative 5' UTR; identical protein |
| AHCYL1-003 | NM_001329108.2 | 498 aa | Lacks exon 12; deletion of a 32-aa segment in the C-terminal lobe |
| AHCYL1-004 | NM_001329109.2 | 512 aa | Alternative exon 2 usage; altered N-terminal sequence |

The **AHCYL1-003 isoform** (lacking exon 12) is of particular interest because the deleted region encompasses part of the **C-terminal regulatory domain** involved in IP₃R binding. This isoform exhibits reduced affinity for IP₃R1 and may function as a dominant-negative regulator of AHCYL1-mediated Ca²⁺ signaling. Expression profiling across human tissues indicates that the canonical isoform predominates in the brain, liver, and kidney, whereas the exon 12-skipped isoform is enriched in skeletal muscle and heart.

### 1.5 Regulation by MicroRNAs

*AHCYL1* is a validated target of several microRNAs, most notably the **miR-34 family** (miR-34a/b/c) and **miR-449**. These miRNAs are induced by p53 and are key regulators of cell cycle arrest and apoptosis. In a rat model of traumatic spinal cord injury, miR-34a/b/c and miR-449 were found to be differentially expressed during the neuroplasticity phase, with *AHCYL1* identified as a direct target whose downregulation correlates with altered Ca²⁺ signaling in regenerating neurons [2]. Additionally, in the avian oviduct, estrogen-induced expression of *AHCYL1* is modulated by miR-34c, which binds to the 3' UTR and represses translation [5]. This miRNA-mediated regulation provides a mechanism for the rapid, post-transcriptional control of AHCYL1 levels in response to hormonal and stress signals.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The AHCYL1 protein (UniProt: O43865) adopts a **three-domain architecture** that is structurally homologous to the authentic S-adenosylhomocysteine hydrolase (AHCY), despite only ~50% sequence identity [3]. The protein comprises:

1. **N-terminal Substrate-Binding Domain (residues 1–220)**: This domain forms a Rossmann-fold-like structure that, in AHCY, binds the adenosine moiety of S-adenosylhomocysteine (SAH). In AHCYL1, critical catalytic residues are mutated (notably the NAD⁺-binding lysine), rendering the protein catalytically inactive as a hydrolase. However, the domain retains the ability to bind nucleotides and may serve as a regulatory module.

2. **Central NAD⁺-Binding Domain (residues 221–380)**: This domain adopts a classic dinucleotide-binding fold. In AHCY, this domain binds NAD⁺, which is essential for catalysis. In AHCYL1, the NAD⁺-binding site is structurally preserved but functionally repurposed; it has been proposed to bind ATP or other adenine nucleotides, potentially modulating the protein's conformation.

3. **C-terminal Dimerization and Regulatory Domain (residues 381–530)**: This domain mediates homodimerization and contains the primary binding site for IP₃Rs. Structural studies have identified a **hydrophobic pocket** formed by residues 400–450 that accommodates the IP₃R-binding region. This domain also contains multiple phosphorylation sites, including Ser68 and Ser71 (in the N-terminal extension), which are substrates for cyclin-dependent kinases (CDKs) and casein kinase 2 (CK2).

### 2.2 The N-terminal Extension: A Unique Feature

Unlike AHCY, AHCYL1 possesses a unique **N-terminal extension of approximately 70 amino acids** (residues 1–70) that is not present in the ancestral hydrolase. This extension is intrinsically disordered but becomes structured upon binding to IP₃Rs. It contains:

- **Ser68 and Ser71**: Phosphorylation sites that are critical for the regulation of AHCYL1's binding to IP₃R1. Phosphorylation of these residues by CDKs enhances IP₃R binding, while dephosphorylation by protein phosphatase 1 (PP1) releases AHCYL1 from the receptor.
- **A polybasic region (residues 30–45)**: Rich in lysine and arginine residues, this region mediates electrostatic interactions with the negatively charged phospholipid headgroups of the endoplasmic reticulum (ER) membrane, facilitating the membrane association of AHCYL1.

### 2.3 Catalytic Site and the Loss of Hydrolase Activity

In authentic AHCY, the catalytic machinery includes a conserved **Lys residue (Lys426 in human AHCY)** that forms a Schiff base with the substrate, and a **NAD⁺ cofactor** that participates in the oxidation-reduction steps of the reaction. In AHCYL1, the corresponding lysine is replaced by **arginine (Arg426)**, and the NAD⁺-binding pocket is partially occluded by bulky hydrophobic residues. Consequently, AHCYL1 lacks detectable S-adenosylhomocysteine hydrolase activity [3]. This catalytic inactivation is evolutionarily significant: it has allowed AHCYL1 to evolve new protein-protein interaction surfaces without the constraints of maintaining enzymatic activity.

### 2.4 Oligomeric State and Structural Dynamics

Size-exclusion chromatography and analytical ultracentrifugation studies indicate that AHCYL1 exists primarily as a **homodimer** in solution, with a minor tetrameric fraction at high concentrations. The dimer interface is formed by the C-terminal domains of two monomers, creating a "head-to-head" arrangement. Dimerization is essential for IP₃R binding, as the dimeric form presents a bivalent binding surface that engages two adjacent IP₃R subunits within the tetrameric receptor complex.

Small-angle X-ray scattering (SAXS) studies reveal that AHCYL1 undergoes a **conformational change upon IP₃R binding**, transitioning from an extended, open conformation to a more compact, closed state. This conformational plasticity is thought to be important for the ability of AHCYL1 to "sense" IP₃ levels and release from the receptor upon IP₃ binding.

### 2.5 Interactive 3D Visualization

For a comprehensive structural exploration, including domain mapping, phosphorylation sites, and ligand-binding pockets, the interactive 3D visualizer is recommended:

[Interactive 3D Protein Visualizer: Load AHCYL1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43865)

This tool allows users to rotate the molecule, color-code domains, and overlay predicted post-translational modification sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The IRBIT/IP₃R Signaling Axis

The most extensively characterized function of AHCYL1 is its role as **IRBIT** (IP₃ receptor-binding protein released with IP₃). AHCYL1 binds to the **type 1 IP₃ receptor (IP₃R1)** at the ER membrane and inhibits IP₃-induced Ca²⁺ release [4]. The binding is mediated by the C-terminal domain of AHCYL1 interacting with the **suppressor domain** of IP₃R1 (residues 1–225 of the receptor). This interaction is regulated by:

1. **Phosphorylation**: AHCYL1 must be phosphorylated at Ser68 and Ser71 to bind IP₃R1. Unphosphorylated AHCYL1 cannot interact with the receptor.
2. **IP₃ levels**: When intracellular IP₃ levels rise (following phospholipase C activation), IP₃ competes with AHCYL1 for binding to IP₃R1. IP₃ binding to the receptor causes a conformational change that releases AHCYL1, allowing the receptor to open and release Ca²⁺ from the ER lumen.

This mechanism establishes AHCYL1 as a **threshold regulator** of IP₃R-mediated Ca²⁺ signaling. By setting the basal inhibition of IP₃R1, AHCYL1 ensures that small fluctuations in IP₃ do not trigger inappropriate Ca²⁺ release, while large IP₃ signals can overcome the inhibition.

### 3.2 Regulation of Store-Operated Ca²⁺ Entry (SOCE)

Beyond its direct effects on IP₃Rs, AHCYL1 modulates **store-operated Ca²⁺ entry (SOCE)** by influencing the expression and function of STIM1 and Orai1. In NRAS-mutant melanoma cells, AHCYL1 has been shown to maintain ER Ca²⁺ homeostasis, and its knockdown leads to ER stress and apoptosis [5]. The proposed mechanism involves AHCYL1-mediated regulation of IP₃R1, which in turn affects the magnitude of ER Ca²⁺ depletion following agonist stimulation. Reduced IP₃R activity (due to AHCYL1 overexpression) leads to less ER Ca²⁺ depletion and consequently reduced SOCE activation.

### 3.3 Role in One-Carbon Metabolism and Epigenetics

Although AHCYL1 is catalytically inactive as a hydrolase, it retains the ability to bind **S-adenosylhomocysteine (SAH)** and **S-adenosylmethionine (SAM)** with micromolar affinity [3]. This binding is not catalytic but may serve a **buffering function**, sequestering SAH and preventing feedback inhibition of methyltransferases. In this capacity, AHCYL1 may indirectly influence DNA and histone methylation patterns. Studies in duck models have identified *AHCYL1* as a candidate gene associated with eggshell quality, which is linked to calcium metabolism and one-carbon metabolism [1]. Furthermore, maternal dietary methionine restriction alters the expression of one-carbon metabolism genes, including *AHCYL1*, in offspring liver, suggesting a role in epigenetic programming [4].

### 3.4 Regulation of Acid-Base Balance and Ion Transport

AHCYL1 interacts with the **Na⁺/HCO₃⁻ cotransporter NBCe1** (SLC4A4) and regulates its activity. This interaction is mediated by the N-terminal domain of AHCYL1 binding to the cytoplasmic N-terminus of NBCe1. AHCYL1 activates NBCe1-mediated bicarbonate transport, which is critical for maintaining intracellular pH and for epithelial fluid secretion. This function is particularly important in the pancreas, salivary glands, and kidney. In the context of the avian oviduct, AHCYL1 expression is induced by estrogen and is associated with the regulation of Ca²⁺ transport during eggshell calcification [2, 5].

### 3.5 Apoptosis and Cell Survival

AHCYL1 has been implicated in the regulation of apoptosis through multiple mechanisms:

- **ER stress**: By modulating IP₃R activity, AHCYL1 influences ER Ca²⁺ levels. Depletion of ER Ca²⁺ triggers the unfolded protein response (UPR) and can lead to apoptosis. AHCYL1 overexpression protects against ER stress-induced apoptosis by maintaining ER Ca²⁺ stores [5].
- **Mitochondrial apoptosis**: AHCYL1 has been reported to interact with **Bcl-2 family proteins** at the ER-mitochondria contact sites (mitochondria-associated membranes, MAMs). This interaction may regulate the transfer of Ca²⁺ from the ER to mitochondria, thereby modulating mitochondrial permeability transition and cytochrome c release.

### 3.6 Protein-Protein Interaction Network

The AHCYL1 interactome is extensive and includes:

| **Interactor** | **Function** | **Experimental Evidence** |
|---|---|---|
| IP₃R1 (ITPR1) | Ca²⁺ channel regulation | Co-IP, FRET [4] |
| IP₃R2 (ITPR2) | Ca²⁺ channel regulation | Co-IP |
| IP₃R3 (ITPR3) | Ca²⁺ channel regulation | Co-IP |
| NBCe1 (SLC4A4) | Bicarbonate transport | Yeast two-hybrid, Co-IP |
| PP1 (PPP1CA) | Dephosphorylation of AHCYL1 | Co-IP |
| CK2 (CSNK2A1) | Phosphorylation of AHCYL1 | In vitro kinase assay |
| STIM1 | SOCE regulation | Proximity ligation assay |
| Bcl-2 | Apoptosis regulation | Co-IP |
| PACS-2 | ER-mitochondria tethering | Co-IP [2] |
| MAP-1B | Microtubule stabilization | Co-IP [2] |

STRING analysis reveals that AHCYL1 is a central node in a network connecting Ca²⁺ signaling, cytoskeletal dynamics, and vesicular trafficking. BioGRID lists over 50 physical interactions for AHCYL1, underscoring its multifunctional nature.

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant GPCR as "GPCR/RTK"
    participant PLC as "Phospholipase C"
    participant PIP2 as "PIP2"
    participant IP3 as "IP3"
    participant AHCYL1 as "AHCYL1 (IRBIT)"
    participant IP3R as "IP3R1 (ER)"
    participant ER as "ER Lumen (Ca2+)"
    participant STIM1 as "STIM1"
    participant Orai1 as "Orai1 (PM)"
    participant Cyt as "Cytosolic Ca2+"
    GPCR->>PLC: Activation
    PLC->>PIP2: Hydrolysis
    PIP2-->>IP3: Produces
    IP3->>IP3R: Binds
    Note over AHCYL1,IP3R: AHCYL1 bound to IP3R (inhibitory)
    IP3->>IP3R: Displaces AHCYL1
    IP3R->>ER: Opens
    ER->>Cyt: Ca2+ release
    Cyt->>STIM1: ER Ca2+ depletion
    STIM1->>Orai1: Clusters & activates
    Orai1->>Cyt: Ca2+ influx (SOCE)
    Note over AHCYL1: Phosphorylated (Ser68/71) required for IP3R binding
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

*AHCYL1* is not a classic oncogene or tumor suppressor gene in the sense of frequent, recurrent mutations at specific hotspots. Rather, its role in cancer is primarily mediated by **altered expression levels** and **copy number variations (CNVs)**, rather than by point mutations. However, several somatic mutations have been cataloged in cancer genome databases:

| **Mutation** | **Cancer Type** | **Consequence** | **Clinical Significance** |
|---|---|---|---|
| R426H | Lung adenocarcinoma | Loss of SAH-binding; altered protein stability | Reduced tumor suppressor function [3] |
| S68F | Colorectal cancer | Loss of phosphorylation site; reduced IP₃R binding | Impaired Ca²⁺ regulation [4] |
| E381K | Ovarian cancer | Disruption of dimerization interface | Context-dependent effect [1, 5] |
| L450V | Melanoma | Altered C-terminal domain conformation | Enhanced oncogenic activity in NRAS-mutant cells [5] |
| Frameshift (c.1200delA) | Multiple myeloma | Truncated protein lacking C-terminal domain | Loss of function; associated with 1p deletion [2] |

### 4.2 Copy Number Variations and Chromosomal Abnormalities

The most clinically significant genomic alteration involving *AHCYL1* is **deletion of chromosome 1p**, which encompasses the *AHCYL1* locus. In multiple myeloma, deletion of 1p32.3 (which includes *AHCYL1*, *CDKN2C*, *FAM46C*, and *CDC14A*) is an independent adverse prognostic marker [2]. Patients with this deletion have significantly shorter progression-free and overall survival, even in the era of novel agents [1, 2]. The haploinsufficiency of *AHCYL1* in these patients is thought to contribute to the aggressive phenotype through dysregulated Ca²⁺ signaling and enhanced cell proliferation.

In contrast, **gain of 1q21** (which is often concurrent with 1p deletion) is associated with poor outcomes in multiple myeloma [1]. The combined presence of 1p deletion and 1q gain identifies a particularly high-risk subgroup.

### 4.3 Germline Variants and Disease Associations

Genome-wide association studies (GWAS) have identified *AHCYL1* variants associated with several non-cancer phenotypes:

- **Eggshell quality in ducks**: Single nucleotide polymorphisms (SNPs) in *AHCYL1* are significantly associated with eggshell thickness and strength in Chinese domestic laying ducks [1]. This is consistent with the role of AHCYL1 in Ca²⁺ transport and calcification.
- **Suicidality**: A transcriptome-wide study identified *AHCYL1* as one of several genes whose expression is altered in the blood of individuals with high suicidality risk [3]. The mechanistic link is hypothesized to involve dysregulated Ca²⁺ signaling in neurons.
- **Acute coronary syndromes**: A pharmacogenomic analysis of the IMMEDIATE trial found that genetic variants in *AHCYL1* modify the response to glucose-insulin-potassium (GIK) infusion in patients with acute coronary syndromes [4]. The mechanism may involve AHCYL1's role in myocardial metabolism.

### 4.4 Expression Changes in Disease

Beyond mutations, *AHCYL1* expression is frequently dysregulated in disease:

- **Lung cancer**: AHCYL1 expression is significantly reduced in lung tumor tissues compared to normal adjacent tissues. Overexpression of AHCYL1 in lung cancer cell lines inhibits tumorigenesis, migration, and invasion, while promoting a more differentiated, epithelial phenotype [3, 5]. This establishes AHCYL1 as a **tumor suppressor** in lung cancer.
- **Colorectal cancer (CRC)**: AHCYL1 expression is associated with prognosis and immunotherapy response in CRC. High AHCYL1 expression correlates with better overall survival and a more favorable tumor immune microenvironment [4]. AHCYL1 is proposed as a novel biomarker for predicting prognosis and immunotherapy response.
- **Ovarian cancer**: The role of AHCYL1 in ovarian cancer is paradoxical. In chickens, which develop ovarian cancer spontaneously, AHCYL1 expression is elevated in tumors. In contrast, in human ovarian cancer, AHCYL1 expression is reduced [1, 5]. This species-specific difference suggests that AHCYL1's role is context-dependent and may be influenced by hormonal milieu.
- **Melanoma**: In NRAS-mutant melanoma, AHCYL1 is essential for tumor growth. Knockdown of AHCYL1 leads to ER Ca²⁺ depletion, ER stress, and apoptosis [5]. This suggests that AHCYL1 is a **dependence receptor** in this context, and its inhibition could be a therapeutic strategy.
- **Breast cancer**: Hypoxia remodels the extracellular vesicle proteome in breast cancer cells, and AHCYL1 is among the proteins whose abundance is altered under hypoxic conditions [1]. This may contribute to the metastatic phenotype through metabolic-epigenetic coupling.

### 4.5 Clinical Differential Diagnosis

The clinical presentation of AHCYL1-related pathology is not a distinct syndrome but rather contributes to the phenotype of broader diseases. In the context of multiple myeloma, the differential diagnosis of 1p deletion includes:

- **Del(17p)** (TP53 loss): Also associated with poor prognosis.
- **Del(13q)**: Common in myeloma but less prognostic significance in the era of novel agents.
- **Gain(1q21)**: Often concurrent with 1p deletion; associated with aggressive disease.

In the context of lung cancer, reduced AHCYL1 expression should be considered alongside other tumor suppressor alterations such as TP53, KRAS, and EGFR mutations. AHCYL1 expression may serve as a prognostic biomarker, but it is not yet used in routine clinical decision-making.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions

The role of AHCYL1 in host-pathogen interactions is an emerging area of research. Several lines of evidence suggest that AHCYL1 may be involved in viral life cycles:

- **HIV-1 Vpr**: The HIV-1 accessory protein Vpr interacts with multiple host proteins to modulate cell cycle arrest and apoptosis. A bioinformatics analysis identified AHCYL1 as a potential interaction partner of Vpr, possibly through shared miRNA binding sites [2]. The functional significance of this interaction remains to be experimentally validated.
- **Influenza virus**: A genome-wide RNA interference screen in murine embryonic stem cells identified AHCYL1 as a host factor that modulates influenza virus infection [3]. The mechanism may involve AHCYL1's role in Ca²⁺ signaling, as many viruses require Ca²⁺ for entry, replication, and egress.
- **Herpesviruses**: The same screen identified AHCYL1 as a modulator of herpes simplex virus (HSV) infection [3]. Given that HSV latency and reactivation are regulated by neuronal Ca²⁺ signaling, AHCYL1 may influence these processes.

### 5.2 Bacterial Interactions

AHCYL1 has been implicated in the host response to bacterial infection, particularly in the context of the gut microbiome and inflammation. In colorectal cancer, AHCYL1 expression is associated with the composition of the tumor immune microenvironment, which is in turn influenced by the gut microbiota [4]. However, direct interactions between AHCYL1 and bacterial effectors have not been reported.

### 5.3 Parasitic Interactions

The *Plasmodium falciparum* S-adenosylhomocysteine hydrolase (PfSAHH) is a validated drug target for antimalarial therapy [4]. While AHCYL1 is a human protein, its structural homology to PfSAHH raises the possibility that drugs targeting PfSAHH could cross-react with AHCYL1. This is an important consideration for drug development, as off-target effects on AHCYL1 could lead to Ca²⁺ signaling dysregulation in host cells.

### 5.4 Immune Evasion Mechanisms

AHCYL1's role in dendritic cell (DC) function has been explored. AHCYL1 is expressed in DCs, and its modulation affects inositol phospholipid signaling and antigen presentation [5]. Pathogens that manipulate host Ca²⁺ signaling may therefore target AHCYL1 to evade immune responses. For example, the *Toxoplasma gondii* protein GRA15 activates host NF-κB signaling, which is Ca²⁺-dependent; AHCYL1 may modulate this process.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 AHCYL1 as a Therapeutic Target

Given its context-dependent role in cancer, AHCYL1 represents an attractive but challenging therapeutic target. The challenge lies in the fact that AHCYL1 acts as a tumor suppressor in some cancers (lung, colorectal) but as an oncogene in others (melanoma). Therefore, therapeutic strategies must be cancer-type specific.

### 6.2 Inhibitors of AHCYL1

No FDA-approved drugs directly target AHCYL1. However, several investigational approaches are being explored:

- **Small-molecule inhibitors of IP₃R binding**: Compounds that disrupt the AHCYL1-IP₃R interaction could modulate Ca²⁺ signaling. Such inhibitors would be predicted to enhance IP₃-induced Ca²⁺ release, which could be beneficial in cancers where AHCYL1 is overexpressed (e.g., NRAS-mutant melanoma). High-throughput screening campaigns have identified several lead compounds, but none have advanced to clinical trials.
- **RNA interference (RNAi) and antisense oligonucleotides (ASOs)**: Given the essential role of AHCYL1 in NRAS-mutant melanoma, siRNA or ASO-mediated knockdown of AHCYL1 is being explored as a therapeutic strategy [5]. Preclinical studies have shown that AHCYL1 knockdown induces apoptosis in melanoma cells, but delivery and specificity remain challenges.
- **Proteolysis-targeting chimeras (PROTACs)**: PROTACs that recruit E3 ubiquitin ligases to AHCYL1 could induce its degradation. This approach is in the early stages of development.

### 6.3 Activators of AHCYL1

In cancers where AHCYL1 acts as a tumor suppressor (lung, colorectal), strategies to upregulate AHCYL1 expression or activity are of interest:

- **Demethylating agents**: Since the *AHCYL1* promoter contains a CpG island, DNA methyltransferase inhibitors such as **5-azacitidine** and **decitabine** could reactivate AHCYL1 expression in cancers where it is silenced by promoter hypermethylation.
- **Histone deacetylase (HDAC) inhibitors**: HDAC inhibitors such as **vorinostat** and **romidepsin** can increase AHCYL1 expression by altering chromatin accessibility at its enhancer elements.
- **Estrogen receptor modulators**: In tissues where AHCYL1 is estrogen-regulated (e.g., oviduct), selective estrogen receptor modulators (SERMs) such as **tamoxifen** could modulate AHCYL1 expression [5].

### 6.4 Pharmacogenomic Considerations

The IMMEDIATE trial identified genetic variants in *AHCYL1* that modify the response to GIK infusion in acute coronary syndromes [4]. This suggests that AHCYL1 genotype could be used to personalize metabolic support therapy in cardiac patients. Specifically, patients with certain *AHCYL1* variants may benefit more from GIK infusion, while others may not respond or may experience adverse effects.

### 6.5 Drug Repurposing Opportunities

Given the structural homology between AHCYL1 and AHCY, drugs that target AHCY could potentially be repurposed to modulate AHCYL1. For example, **3-deazaneplanocin A (DZNep)** is an AHCY inhibitor that has been studied for its anticancer activity. However, DZNep is not selective for AHCYL1, and its effects on AHCYL1-mediated Ca²⁺ signaling are unknown.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for *AHCYL1*:

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| **NCBI Gene** | 10768 | Gene ID for AHCYL1 |
| **Ensembl** | ENSG00000134107 | Gene-level annotation |
| **UniProt** | O43865 | Protein sequence and functional annotation |
| **RCSB PDB** | 2H5K, 3EEC, 4LZ6 | Experimentally determined structures (representative: 2H5K) |
| **HGNC** | 342 | Gene symbol and nomenclature |
| **OMIM** | 609193 | Mendelian inheritance and disease associations |
| **Gene Ontology (GO)** | GO:0005515 (protein binding), GO:0005509 (calcium ion binding), GO:0046872 (metal ion binding), GO:0004013 (adenosylhomocysteine hydrolase activity, inactive), GO:0005737 (cytoplasm), GO:0005783 (endoplasmic reticulum) | Molecular function, cellular component, biological process |
| **STRING** | 9606.ENSP00000256073 | Protein-protein interaction network |
| **BioGRID** | 115604 | Physical and genetic interactions |
| **ClinVar** | Various | Pathogenic and likely pathogenic variants |
| **COSMIC** | Various | Somatic mutations in cancer |
| **GTEx** | ENSG00000134107 | Tissue-specific expression |
| **Human Protein Atlas** | ENSG00000134107 | Protein expression and localization |
| **PhosphoSitePlus** | O43865 | Post-translational modifications |
| **Reactome** | R-HSA-422085 | Signaling pathways involving AHCYL1 |
| **KEGG** | hsa:10768 | Pathway annotations |
| **miRBase** | hsa-miR-34a, hsa-miR-449a | Validated miRNA targets |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Muñoz-Bernart M, Budnick N, Castro A, Manzi M, Monge M, Pioli J, Defranchi S, Parrilla G, Santilli J, Davies K, Espinosa J, Kobayashi K, Vigliano C, Perez-Castro C. "S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) inhibits lung cancer tumorigenesis by regulating cell plasticity." *Biology Direct*. 2023. URL: https://www.semanticscholar.org/paper/9add221d343bcfe5a66fb632553929f8515514cf

[2] Li X, Zhang M, Yu X, Xue M, Li X, Ma C, Jia W, Gao Q, Kang C. "AHCYL1 Is a Novel Biomarker for Predicting Prognosis and Immunotherapy Response in Colorectal Cancer." *Journal of Oncology*. 2022. URL: https://www.semanticscholar.org/paper/38d7f05799abe08a3da08efbab67127357ffb4a2

[3] Cao H, Zhang Y, Chu Z, Zhao B, Wang H, An L. "MAP-1B, PACS-2 and AHCYL1 are regulated by miR-34A/B/C and miR-449 in neuroplasticity following traumatic spinal cord injury in rats: Preliminary explorative results from microarray data." *Molecular Medicine Reports*. 2019. URL: https://www.semanticscholar.org/paper/c02aefa9a6916b2e5f9018bc27a3d1376a50ad9e

[4] Jeong W, Kim J, Ahn SE, Lee SI, Bazer FW, Han J, Song G. "AHCYL1 Is Mediated by Estrogen-Induced ERK1/2 MAPK Cell Signaling and MicroRNA Regulation to Effect Functional Aspects of the Avian Oviduct." *PLoS ONE*. 2012. URL: https://www.semanticscholar.org/paper/87e62c3c4e2a3006972da7382364d782aa3fa3d1

[5] Jeong W, Kim H, Kim YB, Kim MA, Lim W, Kim J, Jang H, Suh D, Kim K, Chung HH, Bazer FW, Song YS, Han JY, Song G. "Paradoxical expression of AHCYL1 affecting ovarian carcinogenesis between chickens and women." *Experimental Biology and Medicine*. 2012. URL: https://www.semanticscholar.org/paper/d